Subscribe

Rheumatoid Arthritis

Currently, disease-modifying antirheumatic drugs (DMARDs) are classified as either biological or nonbiological. According to a recent study, however, this classification scheme is limiting and does not distinguish between the different types of DMARDs.
Adult patients with rheumatoid arthritis (RA) may benefit from subcutaneous methotrexate (MTX) compared with oral administration of the drug, recent study findings suggest.
Seville, Spain—Using a panel of 4 biomarkers is effective in selecting patients with rheumatoid arthritis who are most likely to meet the American College of Rheumatology (ACR) criteria for 50% improvement (ACR50) to 4 mg/kg/day of tocilizumab, according to a study presented at the recent 2014 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (Siebuhr AS. Seville, Spain: World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases; 2014. Abstract OC24).
Zitter Health Insights (ZHI) recently released the latest edition of its Co-Pay Offset Monitor, a publication that serves as a research tool to help identify trends in copay assistance. The group surveyed 100 rheumatologists, 100 patients who had used copay offset programs (COPs) for their medications over the previous 6 months, and 25 specialty pharmacists.
Close to 17% of patients with rheumatoid arthritis (RA) may have depression, according to the results of a systematic review and meta-analysis.
San Diego, CA—The concept of “treat-to-target” (T2T) is key to optimizing disease control and outcomes in patients with rheumatoid arthritis (RA).
Patients with rheumatoid arthritis (RA) receive different care depending on where they live, and this has an impact on their outcomes, according to a study presented at the 2013 American College of Rheumatology (ACR) Meeting. Patients with RA who live in the Mountain region are treated according to ACR guidelines more often than patients who live in other regions of the United States.
By Wayne Kuznar San Diego, CA—Developments in therapeutics for rheumatoid arthritis (RA) have been taking place at breathtaking speed. Biologic agents have greatly increased the ability to improve the lives of patients with RA, and integrating their use with conventional agents will lead to optimal patient outcomes, said Ronald van Vollenhoven, MD, PhD, at the Rational Approach to Treating RA symposium presented during the 2013 American College of Rheumatology (ACR) meeting. Expect additional biologic agents, biosimilars, and oral agents with efficacies comparable to biologics, he said.
By Phoebe Starr San Diego, CA—CT-P13 showed 2-year efficacy and safety equivalent to that of infliximab (Remicade) in patients with rheumatoid arthritis (RA) on assessments of disease activity and safety, according to a study presented at the 2013 American College of Rheumatology (ACR) meeting.
By Wayne Kuznar San Diego, CA—Subcutaneous claz­akizumab, an investigational monoclonal antibody against interleukin (IL)-6, was found to be effective with or without methotrexate in adults with moderate-to-severe active rheumatoid arthritis (RA) who have an inadequate response to methotrexate at key end points, according to a phase 2b study presented at the 2013 American College of Rheumatology (ACR) meeting.
Page 7 of 9
Results 61 - 70 of 87
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology